Director's Dealing • Jun 10, 2021
Director's Dealing
Open in ViewerOpens in native device viewer
Company Announcement
COPENHAGEN, Denmark, June 10, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
|---|---|---|---|---|---|
| a) | Name | Henrik Birk | |||
| 2. | Reason for the notification | ||||
| a) | Position/status | Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S |
|||
| b) | Initial notification/Amendment | Initial notification | |||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) | Name | Bavarian Nordic A/S | |||
| b) | LEI | 2138006JCDVYIN6INP51 | |||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
| a) | Description of the financial instrument, type of instrument |
Shares | |||
| Identification code | DK0015998017 | ||||
| b) | Nature of the transaction | Exercise of warrants | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| DKK 205.80 | 12,191 | ||||
| d) | Aggregated information - Aggregated volume - Price |
12,191 DKK 2,508,907.80 |
|||
| e) | Date of the transaction | 2021-06-10 | |||
| f) | Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
| 1. | Details of the person discharging managerial responsibilities/person closely associated | ||
|---|---|---|---|
| a) | Name | Henrik Birk | |
| 2. | Reason for the notification | ||
| a) | Position/status | Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S |
|
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
| a) | Name | Bavarian Nordic A/S |
Page 1 of 2
| b) | LEI | 2138006JCDVYIN6INP51 | |||
|---|---|---|---|---|---|
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
| a) | Description of the financial instrument, type of instrument |
Shares | |||
| Identification code | DK0015998017 | ||||
| b) | Nature of the transaction | Sale | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| DKK 281.67 | 3,349 | ||||
| d) | Aggregated information - Aggregated volume - Price |
3,349 DKK 943,308.90 |
|||
| e) | Date of the transaction | 2021-06-09 | |||
| f) | Place of the transaction | Nasdaq Copenhagen A/S, XCSE |
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a longterm supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine based on an in-licensed capsid virus-like particle technology. The vaccine candidate, ABNCoV2, is currently being investigated in clinical trials. For more information visit www.bavarian-nordic.com.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43 US: Graham Morrell, Paddock Circle Advisors, [email protected], Tel: +1 781 686 9600
Company Announcement no. 24 / 2021
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.